Medicare National Payment Rate for Tutivia™ and Clarava™ Effective as of January 1, 2024
Verici Dx announces announces that the Centers for Medicare & Medicaid Services (“CMS”) released the Clinical Laboratory Fee Schedule (“CLFS”) payment rate
Home »
Verici Dx Clinical Laboratory achieves CAP accreditation
Verici Dx announces that its testing laboratory in Franklin, TN, has been accredited by the internationally recognised College of American Pathology (CAP)
Tutivia™ validation study published in The American Journal of Transplantation
Verici Dx announces successful pivotal international validation study for TutiviaTM to improve patient outcomes
ISO 27001 Information Security Certification Achieved
Verici Dx announces that it has attained the ISO 27001 certification for its Information Security Management System (“ISMS”).
Verici Dx plc reaches a global licensing and commercialization agreement with Thermo Fisher Scientific
Agreement grants rights to further develop an assay for pre-transplant prognostic testing.
Cardiff, U.K. (November 15, 2023) – Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced that it has signed an exclusive global licensing agreement with Thermo Fisher Scientific, the world leader in serving science, to further develop an assay for pre-transplant prognostic testing for risk of early kidney rejection.
Clarava™ poster to be presented at ASN Kidney Week
Verici Dx announces announces international clinical validation study data to be presented at the largest global gathering of kidney health professionals
Half-year report
Continuing to build the foundations for commercial success. Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces its unaudited interim results for the six months ended 30 June 2023. Operational highlights (including post-period end) Initial revenues following the commercial launch of our first product, Tutivia™, the Company’s post-transplant prognostic […]
CLIA Certificate of Compliance update
US clinical laboratory now fully accredited in 49 states Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that further to the RNS dated 2 March 2023, the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional […]
